EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunomodulation by endothelial cells: prospects for cancer therapy

Halima Alnaqbi, Lisa M Becker, Mira Mousa, Fatima Alshamsi, Sarah K Azzam, Besa Emini Veseli, Lauren A Hymel, Khalood Alhosani, Marwa Alhusain, Massimiliano Mazzone, Habiba Alsafar, Peter Carmeliet

Trends in Cancer · 2024-11 · 10 (11) · 1072-1091

DOI: 10.1016/j.trecan.2024.08.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2024-11. Verfasst von Halima Alnaqbi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biotechnology, Khalifa University, Abu Dhabi, United Arab Emirates; Department of Biomedical Engineering and Biotechnology, Khalifa Univer…. Hauptthemen laut MEDLINE: Neoplasms, Tumor Microenvironment, Endothelial Cells, Immunomodulation. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 155 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Growing evidence highlights the importance of tumor endothelial cells (TECs) in the tumor microenvironment (TME) for promoting tumor growth and evading immune responses. Immunomodulatory endothelial cells (IMECs) represent a distinct plastic phenotype of ECs that exerts the ability to modulate immunity in health and disease. This review discusses our current understanding of IMECs in cancer biology, scrutinizing insights from single-cell reports to compare their characteristics and function dynamics across diverse tumor types, conditions, and species. We investigate possible implications of exploiting IMECs in the context of cancer treatment, particularly examining their influence on the efficacy of existing therapies and the potential to leverage them as targets in optimizing immunotherapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTumor MicroenvironmentEndothelial CellsImmunomodulationImmunotherapyHumansAnimals

Stichwörter der Autor:innen

angiogenesiscancerendothelial cellimmunomodulationimmunotherapytumor

Autor:innen und Institutionen

  • Center for Biotechnology, Khalifa University, Abu Dhabi, United Arab Emirates; Department of Biomedical Engineering and Biotechnology, Khalifa University, Abu Dhabi, United Arab Emirates.
  • Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Department of Oncology, University of Leuven, Leuven, Belgium.
  • Center for Biotechnology, Khalifa University, Abu Dhabi, United Arab Emirates; Department of Public Health and Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates.
  • Center for Biotechnology, Khalifa University, Abu Dhabi, United Arab Emirates; Laboratory of Angiogenesis and Vascular Metabolism, Center for Cancer Biology, VIB, Department of Oncology, University of Leuven, Leuven, Be…
  • Center for Biotechnology, Khalifa University, Abu Dhabi, United Arab Emirates.
  • Department of Biological Sciences, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates.

Zitieren

APA

Alnaqbi, H., Becker, L. M., Mousa, M., Alshamsi, F., Azzam, S. K., Emini Veseli, B., Hymel, L. A., Alhosani, K., Alhusain, M., Mazzone, M., Alsafar, H., & Carmeliet, P. (2024). Immunomodulation by endothelial cells: prospects for cancer therapy. Trends in Cancer, 10(11), 1072-1091. https://doi.org/10.1016/j.trecan.2024.08.002

Vancouver

Alnaqbi H, Becker LM, Mousa M, Alshamsi F, Azzam SK, Emini Veseli B, et al. Immunomodulation by endothelial cells: prospects for cancer therapy. Trends in Cancer. 2024;10(11):1072-1091. doi:10.1016/j.trecan.2024.08.002

BibTeX
@article{Alnaqbi2024,
  author = {Alnaqbi, Halima and Becker, Lisa M and Mousa, Mira and Alshamsi, Fatima and Azzam, Sarah K and Emini Veseli, Besa and Hymel, Lauren A and Alhosani, Khalood and Alhusain, Marwa and Mazzone, Massimiliano and Alsafar, Habiba and Carmeliet, Peter},
  title = {Immunomodulation by endothelial cells: prospects for cancer therapy},
  journal = {Trends in Cancer},
  year = {2024},
  volume = {10},
  number = {11},
  pages = {1072--1091},
  doi = {10.1016/j.trecan.2024.08.002}
}
Kostenlos starten →